drugset / Trial / NCT01719042

Improving Tolerance of Treatment of Pulmonary MAC Infections

NCT01719042

Phase 2 Withdrawn University of Florida
RandomizedCrossoverOpen-labelSupportive care

Summary

The purpose of this study is to improve tolerance of treatment of pulmonary Mycobacterium avium Complex disease via the use of therapeutic drug monitoring and the addition of anti-nausea medication or dietary supplements to the patients' daily drug regimen. The aims of this study are to use (1) Zofran® (Ondansetron 8mg), an anti-nausea medication or (2) a dietary supplement to decrease medication related gastrointestinal side effects of medications used to treat Mycobacterium avium Complex.

Timeline

Start
2013-01
Primary completion
2013-03
Completion
2013-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ondansetron Other / unclassified 8 mg